Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Cerebral deposition of the beta-amyloid peptide (A beta) is an invariant feature of Alzheimer's disease. Since the original isolation and characterization of A beta (ref. 1) and the subsequent cloning of its precursor protein, no direct evidence for the actual production of discrete A beta has been reported. Here we investigate whether A beta is present in human biological fluids using antibodies specific for an epitope within A beta that spans the site of normal constitutive cleavage. These antibodies were used to construct a sandwich-type enzyme-linked immunosorbent assay that detects A beta in cerebrospinal fluid, plasma and conditioned medium of human mixed-brain cells grown in vitro (see also ref. 14). By affinity chromatography, we have purified and sequenced A beta and a novel A beta fragment from human cerebrospinal fluid and conditioned medium of human mixed-brain cell cultures. These findings demonstrate that A beta is produced and released both in vivo and in vitro. These observations offer new opportunities for developing diagnostic tests for Alzheimer's disease and therapeutic strategies aimed at reducing the cerebral deposition of A beta.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“studies that shed light on the physiological role of Aβ in non-diseased brains show that Aβ plays a role in synaptic transmission and is involved in learning and memory formation [18–22].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [18]
In the citing paper
“Recently, we and others have shown that normal processing of the large amyloid f3 protein precursor ({3-APP) secretes 4-kDa A(3 that is readily detected in human cerebrospinal fluid and in medium conditioned by cultured cells (3)(4)(5)(6).”
From Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain (1995) · cites this paper as [3]
In the citing paper
“The demonstration that A-related peptides with the same N terminals as the CTFs documented here are present in conditioned medium of cultured cells (Seubert et al., 1992;Naslund et al., 1994;Simons et al., 1996;Wang et al., 1996;Xu et al., 1998)”
From Alzheimer Amyloid Protein Precursor in the Rat Hippocampus: Transport and Processing through the Perforant Path (1998) · cites this paper as Seubert et al., 1992
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCleavage of Amyloid β Peptide During Constitutive Processing of Its Precursor
Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., McClure, D., & Ward, P. J. (1990) · Science · doi:10.1126/science.2111583 · Cited by 1,410
Self-citationMutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type
Levy, E., Carman, M. D., Fernandez-Madrid, I. J., Power, M. D., Lieberburg, I., van Duinen, S. G., Bots, G. T. A. M., Luyendijk, W., & Frangione, B. (1990) · Science · doi:10.1126/science.2111584 · Cited by 1,381
Self-citationChartier-Harlin, M.-C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., Hardy, J., et al. (1991) · Nature · doi:10.1038/353844a0 · Cited by 1,214
A mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease
Murrell, J., Farlow, M., Ghetti, B., & Benson, M. D. (1991) · Science · doi:10.1126/science.1925564 · Cited by 1,127
Tanzi, R. E., McClatchey, A. I., Lamperti, E. D., Villa-Komaroff, L., Gusella, J. F., & Neve, R. L. (1988) · Nature · doi:10.1038/331528a0 · Cited by 1,096
Cited by
Items 201–300 of 1,726
Modulation of Secreted β-Amyloid Precursor Protein and Amyloid β-Peptide in Brain by Cholesterol
Howland, D. S., Trusko, S. P., Savage, M. J., Reaume, A. G., Lang, D. M., Hirsch, J. D., Maeda, N., Siman, R., Greenberg, B. D., Scott, R. W., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.26.16576 · Cited by 255
Sharples, R. A., Vella, L. J., Nisbet, R. M., Naylor, R., Perez, K., Barnham, K. J., Masters, C. L., & Hill, A. F. (2008) · The FASEB Journal · doi:10.1096/fj.07-9357com · Cited by 254
“More importantly, APP and A have been found to circulate in extracellular fluids, including cerebrospinal fluid and plasma (3, 10, 77, 78), and recent work has confirmed the presence of exosomes in both plasma (79) and in association with neuronal cells (51, 80), providing a possible diagnostic tool for AD.”
Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
Lee, J. C., Kim, S. J., Hong, S., & Kim, Y. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0250-2 · Cited by 253
Amyloid-β as a Modulator of Synaptic Plasticity
Parihar, M. S., & Brewer, G. J. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101020 · Cited by 247
“Soluble Aβ (sAβ) is found, at low concentrations, as a normal constituent of biological fluids [54–56].”
Iwatsubo, T., Saido, T. C., Mann, D. M. A., Lee, V. M.-Y., & Trojanowski, J. Q. (1996) · Europe PMC (PubMed Central) · Cited by 298
The Role of APP Processing and Trafficking Pathways in the Formation of Amyloid β‐Proteina
SELKOE, D. J., YAMAZAKI, T., CITRON, M., PODLISNY, M. B., KOO, E. H., TEPLOW, D. B., & HAASS, C. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb34401.x · Cited by 205
Self-citationNitsch, R. M., Farber, S. A., Growdon, J. H., & Wurtman, R. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.5191 · Cited by 244
Calcium Ionophore Increases Amyloid .beta. Peptide Production by Cultured Cells
Querfurth, H. W., & Selkoe, D. J. (1994) · Biochemistry · doi:10.1021/bi00181a016 · Cited by 245
Self-citationMackic, J. B., Stins, M., McComb, J. G., Calero, M., Ghiso, J., Kim, K. S., Yan, S. D., Stern, D., Schmidt, A. M., Frangione, B., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2029 · Cited by 242
“A soluble monomeric form of A  (sA  ) is normally produced by different types of cells (6) and is present in the circulation and cerebrospinal fluid (CSF) (7, 8) and in brain parenchyma (9).”
BackgroundInfluentialSafiri, S., Ghaffari Jolfayi, A., Fazlollahi, A., Morsali, S., Sarkesh, A., Daei Sorkhabi, A., Golabi, B., Aletaha, R., Motlagh Asghari, K., Hamidi, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1474043 · Cited by 200
Pérez, A., Morelli, L., Cresto, J. C., & Castaño, E. M. (2000) · Neurochemical Research · doi:10.1023/a:1007527721160 · Cited by 240
“form ( 5 ). While Aβ 1-40 is the major species of soluble Aβ in body fluids, Aβ 1-42 is the major component of brain fibrillar deposits (6).”
BackgroundPappolla, M. A., Chyan, Y. J., Poeggeler, B., Frangione, B., Wilson, G., Ghiso, J., & Reiter, R. J. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050018 · Cited by 243
“Although small amounts of Aâ are generated by normal cellular metabolism (Haass et al., 1992; Seubert et al., 1992), it is not yet known whether the Aâ peptides that become incorporated into amyloid fibrils derive from the normally produced pool or from abnormal amyloidogenic processing of APP.”
BackgroundMolecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics
Masters, C. L., Cappai, R., Barnham, K. J., & Villemagne, V. L. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03989.x · Cited by 241
“It can also be assessed in CSF, plasma and even neuronal cultures (Seubert et al. 1992).”
BackgroundNon-A.beta. Component of Alzheimer's Disease Amyloid (NAC) is Amyloidogenic
Iwai, A., Yoshimoto, M., Masliah, E., & Saitoh, T. (1995) · Biochemistry · doi:10.1021/bi00032a006 · Cited by 238
Wogulis, M., Wright, S., Cunningham, D., Chilcote, T., Powell, K., & Rydel, R. E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2381-04.2005 · Cited by 233
“A major constituent of amyloid plaques is the 39 – 43 amino acid amyloid- (A ) protein (Glenner and Wong, 1984), which is constitutively produced by normal cleavage of the membranebound amyloid- precursor protein (Seubert et al., 1992).”
BackgroundLuna-Muñoz, J., Chávez-Macías, L., García-Sierra, F., & Mena, R. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-12410 · Cited by 233
Wertkin, A. M., Turner, R. S., Pleasure, S. J., Golde, T. E., Younkin, S. G., Trojanowski, J. Q., & Lee, V. M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9513 · Cited by 231
Lichtenthaler, S. F., Wang, R., Grimm, H., Uljon, S. N., Masters, C. L., & Beyreuther, K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3053 · Cited by 234
Kuo, Y.-M., Kokjohn, T. A., Kalback, W., Luehrs, D., Galasko, D. R., Chevallier, N., Koo, E. H., Emmerling, M. R., & Roher, A. E. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2222 · Cited by 230
Reactive oxygen species and Alzheimer's disease
Multhaup, G., Ruppert, T., Schlicksupp, A., Hesse, L., Beher, D., Masters, C. L., & Beyreuther, K. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00062-2 · Cited by 227
Aleardi, A. M., Benard, G., Augereau, O., Malgat, M., Talbot, J. C., Mazat, J. P., Letellier, T., Dachary-Prigent, J., Solaini, G. C., & Rossignol, R. (2005) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-005-6631-3 · Cited by 224
Ling, Y., Morgan, K., & Kalsheker, N. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(03)00133-x · Cited by 224
Biomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224
Constitutive secretion of tau protein by an unconventional mechanism
Chai, X., Dage, J. L., & Citron, M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.05.021 · Cited by 224
A review on advances of treatment modalities for Alzheimer's disease
Se Thoe, E., Fauzi, A., Tang, Y. Q., Chamyuang, S., & Chia, A. Y. Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119129 · Cited by 219
Conformational Differences between Two Amyloid β Oligomers of Similar Size and Dissimilar Toxicity
Ladiwala, A. R. A., Litt, J., Kane, R. S., Aucoin, D. S., Smith, S. O., Ranjan, S., Davis, J., Van Nostrand, W. E., & Tessier, P. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.329763 · Cited by 225
Van Dorpe, J., Smeijers, L., Dewachter, I., Nuyens, D., Spittaels, K., Van den Haute, C., Mercken, M., Moechars, D., Laenen, I., Kuiperi, C., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64644-5 · Cited by 225
“It has been shown that Ab is present in the CSF of normal and AD individuals.(19,24) However, the mere presence of Ab in the CSF cannot explain the presence of CAA in the pial vessels in the leptomeninges surrounding the cerebrum and its absence in those surrounding the cerebellum, brain stem, or spinal cord, as it wa…”
Amyloid-type Protein Aggregation and Prion-like Properties of Amyloids
Willbold, D., Strodel, B., Schröder, G. F., Hoyer, W., & Heise, H. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00196 · Cited by 221
Regulation of Amyloid Precursor Protein Cleavage
Mills, J., & Reiner, P. B. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720443.x · Cited by 221
“Most full-length Ab peptides fall into one of two populations known as Ab1–40, terminating at amino acid 40 and comprising;90% of secreted Ab, or Ab1–42, terminating at amino acid 42 and comprising only 10% of secreted Ab (Haass et al., 1992; Seubert et al., 1992).”
BackgroundGiri, R., Shen, Y., Stins, M., Du Yan, S., Schmidt, A. M., Stern, D., Kim, K.-S., Zlokovic, B., & Kalra, V. K. (2000) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2000.279.6.c1772 · Cited by 218
Kawahara, M., Arispe, N., Kuroda, Y., & Rojas, E. (1997) · Biophysical Journal · doi:10.1016/s0006-3495(97)78048-2 · Cited by 219
The role of APP and BACE1 trafficking in APP processing and amyloid-β generation
Zhang, X., & Song, W. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt211 · Cited by 213
“be found in cerebrospinal fluid and media conditioned by cultured cells [66-68].”
BackgroundSuzuki, T., Oishi, M., Marshak, D. R., Czernik, A. J., Nairn, A. C., & Greengard, P. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06360.x · Cited by 216
Physicochemical interactions of amyloid β-peptide with lipid bilayers
Matsuzaki, K. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.02.009 · Cited by 215
Cerebrospinal Fluid Markers for Alzheimer's Disease Evaluated after Acute Ischemic Stroke
Hesse, C., Rosengren, L., Vanmechelen, E., Vanderstichele, H., Jensen, C., Davidsson, P., & Blennow, K. (2000) · Journal of Alzheimer's Disease · doi:10.3233/jad-2000-23-402 · Cited by 216
Oxidative stress and neurodegenerative disorders
Sun, A. Y., & Chen, Y.-M. (1998) · Journal of Biomedical Science · doi:10.1007/bf02255928 · Cited by 215
Turnover of Amyloid β-Protein in Mouse Brain and Acute Reduction of Its Level by Phorbol Ester
Savage, M. J., Trusko, S. P., Howland, D. S., Pinsker, L. R., Mistretta, S., Reaume, A. G., Greenberg, B. D., Siman, R., & Scott, R. W. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-05-01743.1998 · Cited by 213
“Under normal conditions, however, soluble Ab ending at residue 40 is more abundant than the 42 residue form (Haass et al., 1992; Seubert et al., 1992; Shoji et al., 1992; Vigo-Pelfrey et al., 1993).”
BackgroundImpact of Cytokines and Chemokines on Alzheimer’s Disease Neuropathological Hallmarks
Domingues, C., da Cruz e Silva, O. A. B., & Henriques, A. G. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170317113606 · Cited by 203
“Under nonpathological conditions, Aβ1-40 is the peptide predominantly produced while Aβ1-42 is a minor species [26, 27].”
α 2 -macroglobulin associates with β-amyloid peptide and prevents fibril formation
Hughes, S. R., Khorkova, O., Goyal, S., Knaeblein, J., Heroux, J., Riedel, N. G., & Sahasrabudhe, S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3275 · Cited by 216
Chung, H., Brazil, M. I., Soe, T. T., & Maxfield, F. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32301 · Cited by 212
Hyman, B. T., West, H. L., Rebeck, G. W., Buldyrev, S. V., Mantegna, R. N., Ukleja, M., Havlin, S., & Stanley, H. E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3586 · Cited by 212
Systemic Catabolism of Alzheimer's Aβ40 and Aβ42
Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., Rostagno, A., & Frangione, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407668200 · Cited by 209
Regulation of β-Amyloid Secretion by FE65, an Amyloid Protein Precursor-binding Protein
Sabo, S. L., Lanier, L. M., Ikin, A. F., Khorkova, O., Sahasrabudhe, S., Greengard, P., & Buxbaum, J. D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.7952 · Cited by 209
Fluid Biomarkers in Alzheimer Disease
Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208
“FLUID BIOMARKERS FOR AD DIAGNOSIS b-Amyloid Isoforms The discovery that b-amyloid (Ab) is produced during normal cell metabolism and is secreted into the CSF served as the basis for Ab biomarker development (Seubert et al. 1992).”
BackgroundMolecular genetics of Alzheimer's disease: An update
Brouwers, N., Sleegers, K., & Van Broeckhoven, C. (2008) · Annals of Medicine · doi:10.1080/07853890802186905 · Cited by 208
The Toxicity of the Alzheimer's β-Amyloid Peptide Correlates with a Distinct Fiber Morphology
Seilheimer, B., Bohrmann, B., Bondolfi, L., Müller, F., Stüber, D., & Döbeli, H. (1997) · Journal of Structural Biology · doi:10.1006/jsbi.1997.3859 · Cited by 210
High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy.
Suzuki, N., Iwatsubo, T., Odaka, A., Ishibashi, Y., Kitada, C., & Ihara, Y. (1994) · PubMed Central · Cited by 244
Howell, S., Nalbantoglu, J., & Crine, P. (1995) · Peptides · doi:10.1016/0196-9781(95)00021-b · Cited by 204
Metal ions, Alzheimer's disease and chelation therapy
Budimir, A. (2011) · Acta Pharmaceutica · doi:10.2478/v10007-011-0006-6 · Cited by 202
Presenilin, Notch, and the genesis and treatment of Alzheimer's disease
Selkoe, D. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211352598 · Cited by 203
Self-citationYoshimoto, M., Iwai, A., Kang, D., Otero, D. A., Xia, Y., & Saitoh, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9141 · Cited by 203
Increased lipoprotein oxidation in alzheimer’s disease
Schippling, S., Kontush, A., Arlt, S., Buhmann, C., Stürenburg, H.-J., Mann, U., Müller-Thomsen, T., & Beisiegel, U. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00247-6 · Cited by 199
Smith, M. A. (1998) · International Review of Neurobiology · doi:10.1016/s0074-7742(08)60607-8 · Cited by 194
Schöneich, C., Pogocki, D., Hug, G. L., & Bobrowski, K. (2003) · Journal of the American Chemical Society · doi:10.1021/ja036733b · Cited by 198
Sporadic and Familial Cerebral Amyloid Angiopathies
Revesz, T., Holton, J. L., Lashley, T., Plant, G., Rostagno, A., Ghiso, J., & Frangione, B. (2002) · Brain Pathology · doi:10.1111/j.1750-3639.2002.tb00449.x · Cited by 199
“A in CAA may also derive from the CSF, as it can be detected there in both normal individuals and AD patients (27, 51, 106).”
BackgroundThe Neuroprotective Potentiality of Flavonoids on Alzheimer’s Disease
Calderaro, A., Patanè, G. T., Tellone, E., Barreca, D., Ficarra, S., Misiti, F., & Laganà, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314835 · Cited by 194
Metallothioneins in Brain—The Role in Physiology and Pathology
Aschner, M., Cherian, M. G., Klaassen, C. D., Palmiter, R. D., Erickson, J. C., & Bush, A. I. (1997) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1996.8054 · Cited by 200
Inclusion complexation, encapsulation interaction and inclusion number in cyclodextrin chemistry
Song, L. X., Bai, L., Xu, X. M., He, J., & Pan, S. Z. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2008.08.011 · Cited by 198
Characterization of Apolipoprotein J-Alzheimer's Aβ Interaction
Matsubara, E., Frangione, B., & Ghiso, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7563 · Cited by 153
Roßner, S. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00044-6 · Cited by 198
Amyloid β Protein-(1–42) Forms Calcium-permeable, Zn2+-sensitive Channel
Rhee, S. K., Quist, A. P., & Lal, R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13379 · Cited by 195
Skoog, I., Davidsson, P., Aevarsson, Ó., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000068478 · Cited by 194
White, M. R., Kandel, R., Tripathi, S., Condon, D., Qi, L., Taubenberger, J., & Hartshorn, K. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101364 · Cited by 193
“fluid and culture medium of mixed brain cell cultures in an early study [9].”
BackgroundAβ ion channels. Prospects for treating Alzheimer's disease with Aβ channel blockers
Arispe, N., Diaz, J. C., & Simakova, O. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.03.014 · Cited by 193
CSF biomarkers for mild cognitive impairment and early Alzheimer's disease
Andreasen, N., & Blennow, K. (2005) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2004.10.011 · Cited by 193
β-Amyloid peptides as direct cholinergic neuromodulators: a missing link?
Auld, D. S., Kar, S., & Quirion, R. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01144-2 · Cited by 196
Animal models of Alzheimer's disease and evaluation of anti-dementia drugs
Yamada, K., & Nabeshima, T. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00081-4 · Cited by 190
Sprecher, C. A., Grant, F. J., Grimm, G., O'Hara, P. J., Norris, F., Norris, K., & Foster, D. C. (1993) · Biochemistry · doi:10.1021/bi00068a002 · Cited by 193
Goure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt272 · Cited by 190
“It has been suggested that 266 is a conformation-specific antibody that solely recognizes soluble Aβ and readily binds monomeric Aβ [188-190], without binding APP or the C-terminal APP cleavage product of α-secretase [189].”
BackgroundWolf, B. A., Wertkin, A. M., Jolly, Y. C., Yasuda, R. P., Wolfe, B. B., Konrad, R. J., Manning, D., Ravi, S., Williamson, J. R., & Lee, V. M.-Y. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.9.4916 · Cited by 191
Amyloidosis and Alzheimer’s disease
Ghiso, J., & Frangione, B. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00149-7 · Cited by 158
Näslund, J., Thyberg, J., Tjernberg, L. O., Wernstedt, C., Karlström, A. R., Bogdanovic, N., Gandy, S. E., Lannfelt, L., Terenius, L., & Nordstedt, C. (1995) · Neuron · doi:10.1016/0896-6273(95)90079-9 · Cited by 189
Singh, S. K., Srivastav, S., Yadav, A. K., Srikrishna, S., & Perry, G. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7361613 · Cited by 186
“Later findings suggest that the presence of soluble Aβ species in the bodily fluids of many species [84] and in the conditional cell culture media [85] has disproved this concept and inferred a physiological function for Aβ.”
BackgroundApolipoprotein J and Alzheimer's amyloid β solubility
MATSUBARA, E., SOTO, C., GOVERNALE, S., FRANGIONE, B., & GHISO, J. (1996) · Biochemical Journal · doi:10.1042/bj3160671 · Cited by 190
Cummings, B. J., Su, J. H., Cotman, C. W., White, R., & Russell, M. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90038-d · Cited by 189
The Oxidative Stress Metabolite 4-Hydroxynonenal Promotes Alzheimer Protofibril Formation
Siegel, S. J., Bieschke, J., Powers, E. T., & Kelly, J. W. (2007) · Biochemistry · doi:10.1021/bi061853s · Cited by 185
Polyphenols as Potential Metal Chelation Compounds Against Alzheimer’s Disease
Lakey-Beitia, J., Burillo, A. M., La Penna, G., Hegde, M. L., & Rao, K. S. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-200185 · Cited by 177
Biology of Aβ Amyloid in Alzheimer's Disease
Wisniewski, T., Ghiso, J., & Frangione, B. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0147 · Cited by 134
Banks, W. A., Terrell, B., Farr, S. A., Robinson, S. M., Nonaka, N., & Morley, J. E. (2002) · Peptides · doi:10.1016/s0196-9781(02)00261-9 · Cited by 185
McDermott, J. R., & Gibson, A. M. (1997) · Neurochemical Research · doi:10.1023/a:1027325304203 · Cited by 187
Advances in the Cellular and Molecular Biology of the Beta-Amyloid Protein in Alzheimer 's Disease
Sambamurti, K., Greig, N. H., & Lahiri, D. K. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:1:1:1 · Cited by 185
Buxbaum, J. D., Ruefli, A. A., Parker, C. A., Cypess, A. M., & Greengard, P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4489 · Cited by 184
Metal ions as modulators of protein conformation and misfolding in neurodegeneration
Leal, S. S., Botelho, H. M., & Gomes, C. M. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.04.004 · Cited by 183
A Cell Biological Perspective on Alzheimer's Disease
Annaert, W., & De Strooper, B. (2002) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.18.020402.142302 · Cited by 182
Kumar, S., & Walter, J. (2011) · Aging · doi:10.18632/aging.100362 · Cited by 180
Ji, S.-R., Wu, Y., & Sui, S.-F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m104146200 · Cited by 181
Genetics and molecular advances in Alzheimer's disease
Mullan, M., & Crawford, F. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90007-9 · Cited by 182
A β 42 and A β 40: similarities and differences
Qiu, T., Liu, Q., Chen, Y., Zhao, Y., & Li, Y. (2015) · Journal of Peptide Science · doi:10.1002/psc.2789 · Cited by 180
Amyloid-β is an antioxidant for lipoproteins in cerebrospinal fluid and plasma
Kontush, A., Berndt, C., Weber, W., Akopyan, V., Arlt, S., Schippling, S., & Beisiegel, U. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00458-5 · Cited by 180
Amyloid β protein (Aβ) removal by neuroglial cells in culture
Shaffer, L. M., Dority, M. D., Gupta-Bansal, R., Frederickson, R. C. A., Younkin, S. G., & Brunden, K. R. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00055-j · Cited by 182
Effects of in vivo conditions on amyloid aggregation
Owen, M. C., Gnutt, D., Gao, M., Wärmländer, S. K. T. S., Jarvet, J., Gräslund, A., Winter, R., Ebbinghaus, S., & Strodel, B. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00034d · Cited by 182
In-situ atomic force microscopy study of β-amyloid fibrillization
Blackley, H. K. L., Sanders, G. H. W., Davies, M. C., Roberts, C. J., Tendler, S. J. B., & Wilkinson, M. J. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3711 · Cited by 178
Role of gangliosides in Alzheimer’s disease
Yanagisawa, K. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.01.018 · Cited by 180
Ji, Z.-S., Miranda, R. D., Newhouse, Y. M., Weisgraber, K. H., Huang, Y., & Mahley, R. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112109200 · Cited by 177
Pathways to Alzheimer's disease
Hardy, J., Bogdanovic, N., Winblad, B., Portelius, E., Andreasen, N., Cedazo‐Minguez, A., & Zetterberg, H. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12192 · Cited by 176
Genetic dissection of Alzheimer disease, a heterogeneous disorder.
Schellenberg, G. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8552 · Cited by 177
β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease
Buttini, M., Masliah, E., Barbour, R., Grajeda, H., Motter, R., Johnson-Wood, K., Khan, K., Seubert, P., Freedman, S., Schenk, D., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1697-05.2005 · Cited by 176
“The IgG2a isotype monoclonal anti-A antibodies 3D6 [anti-A (1–5)] and 12B4 [anti-A (3–7)] were generated as described previously (Seubert et al., 1992; Bard et al., 2003).”
MethodSelf-citationPeripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease
Gasparini, L., Racchi, M., Binetti, G., Trabucchi, M., Solerte, S. B., Alkon, D., Etcheberrigaray, R., Gibson, G., Blass, J., Paoletti, R., et al. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.1.17 · Cited by 175
Qiu, W. Q., Ye, Z., Kholodenko, D., Seubert, P., & Selkoe, D. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.10.6641 · Cited by 177
Self-citationLannfelt, L., Basun, H., Wahlund, L.-O., Rowe, B. A., & Wagner, S. L. (1995) · Nature Medicine · doi:10.1038/nm0895-829 · Cited by 175
Metadata
- Authors
- Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., McCormack, R., Wolfert, R., Selkoe, D., Lieberburg, I., & Schenk, D.
- Affiliations
- Austrian Academy of Sciences (AT)
- Venue
- Nature
- Published
- 1992-09
- Volume
- 359
- Issue
- 6393
- Pages
- 325-327
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2086278983
- Cited by
- 1,731
- References
- 28
- Citations by year
- 2026: 4 · 2025: 14 · 2024: 32 · 2023: 19 · 2022: 22 · 2021: 31 · 2020: 28 · 2019: 25 · 2018: 35 · 2017: 39 · 2016: 31 · 2015: 48 · 2014: 46 · 2013: 39 · 2012: 50
- FWCI
- 72.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, cerebrospinal fluid, plasma, conditioned medium, sandwich ELISA, affinity chromatography, epitope-specific antibodies, amyloid deposition, diagnostic biomarkers
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Antibodies, Monoclonal, Brain, Cells, Cultured, Cross Reactions, Enzyme-Linked Immunosorbent Assay, Humans, Molecular Sequence Data, Peptide Fragments, Radioimmunoassay, Solubility, Amyloid beta-Peptides, Amyloid beta-Protein Precursor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.